We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · November 07, 2021

Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis

The British Journal of Dermatology


Additional Info

The British Journal of Dermatology
Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Transcriptomics from a Phase 2a Randomized, Multicenter Double-Blinded Study
Br J Dermatol 2021 Oct 23;[EPub Ahead of Print], R Oliver, JG Krueger, S Glatt, P Vajjah, C Mistry, M Page, H Edwards, S Garcet, X Li, B Dizier, A Maroof, M Watling, A El Baghdady, D Baeten, L Ionescu, S Shaw

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading